Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TLI and ATG Conditioning for Allogeneic HCT in Triple Negative Breast Cancer
NCT01375023Phase 2Terminated
- Sponsor
- European Institute of Oncology
- Start
- Jun 2009
- Primary completion
- Jul 2013
- Modality
- Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of antithymocyte globulin rabbit in triple negative breast cancer (TNBC), sponsored by European Institute of Oncology. Started Jun 2009; status: terminated.
02
Drugs
antithymocyte globulin rabbit
03
Conditions
triple negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT01375023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01375023.